Still Constipated After a Normal Colonoscopy? The Gut Bacteria Link Most Treatment Plans Miss
Written by Dr Jeffrey Tu, Consultant Gastroenterologist and Hepatologist (FRACP). Last updated 16 October 2026.
Quick answer: No, this is not it, and "surgery or live with it" is a false choice. A normal colonoscopy means your bowel looks healthy, but it says nothing about how your bowel moves, or what the trillions of bacteria inside it are doing to slow it down. Most people in your position are pushed along a single path: stronger laxatives, then prescription tablets, then motility tests, then pelvic-floor retraining, and finally, for a few, surgery. Almost nobody on that path has their gut microbiome checked, even though methane-producing organisms, a depleted microbiome and an imbalanced one are all known to slow the colon, and all of them can be tested for and treated. If you have been told you are running out of options, that is the missing step.
Key takeaways
A normal colonoscopy checks the bowel lining. It does not measure how fast the bowel moves or what the bacteria inside it are doing.
Methane-producing microbes (intestinal methanogen overgrowth, IMO) and a depleted microbiome are both linked to slower transit.
A breath test and a stool sample can check for them. Both are non-invasive.
Treatment is matched to the result, and can run alongside motility testing, before surgery is discussed.
Why am I still constipated if my colonoscopy was normal?
From my consulting room: in my Sydney rooms I see this scenario regularly: a patient arrives with a clear colonoscopy report and a bag of failed laxatives and prescription tablets, having been told the only options left are pelvic floor therapy or living with it.
Because a colonoscopy checks the lining of your bowel, not how it moves or what lives inside it. You are far from alone: around 15% of people worldwide live with chronic constipation [1]. If your colonoscopy was clear, you have probably been moved along a well-worn ladder, each rung reached only after the one below has failed. See if this looks familiar:
Fibre and over-the-counter laxatives. Psyllium (for example Metamucil), macrogol osmotic laxatives (Movicol, OsmoLax) and stimulant laxatives such as senna or bisacodyl (Dulcolax). These work for many people, but a large group find that they stop working, cause cramping and bloating, or need ever-higher doses.
Prescription medicines. Prucalopride (Resotrans), which stimulates the colon's propulsive contractions, and linaclotide (Constella), which draws fluid into the bowel. Both carry strong recommendations in the 2023 AGA–ACG guideline [2]. In the pivotal prucalopride trial about 31% of patients achieved three or more complete bowel motions a week, versus 12% on placebo [3], which means roughly two in three people did not reach that target.
Neurogastroenterology testing. A specialist motility service measures what the bowel is actually doing. A colonic transit study tracks swallowed markers on X-ray to see whether the whole colon is slow. Anorectal manometry and a balloon-expulsion test check whether the pelvic floor and anal sphincter coordinate properly during a bowel motion [4].
Biofeedback. If the pelvic floor tightens instead of relaxing (dyssynergic defecation), targeted biofeedback retraining is the treatment. In a randomised trial it beat both sham feedback and standard laxative care [5].
Surgery. For people with proven slow-transit constipation who have failed everything above, the final options are sacral nerve stimulation or colectomy, which removes most or all of the colon and joins the small bowel to the rectum [1].
Question | Standard motility pathway | The microbiome lens |
What does a normal colonoscopy show? | No polyps, cancer or visible bowel inflammation | Nothing about transit speed or the gases and chemicals bacteria make |
Why is the bowel slow? | Nerve or muscle sluggishness, cause unknown | Possibly a chemical brake, such as methane, or a loss of bacteria that normally speed the bowel up |
Why do laxatives stop working? | Labelled refractory slow-transit constipation | Laxatives move water through but leave the methane-producing organisms untouched |
What gets tested? | Transit study and anorectal manometry | Breath test (methane at or above 10 ppm) and stool microbiome profile |
Every one of these steps is legitimate and well studied, and a good motility service does exactly what it is designed to do. But it helps to understand what the tests are for. A transit study and manometry clarify the problem: they tell you whether your colon is slow and whether your pelvic floor is the issue. If the pelvic floor is the issue, biofeedback is a real treatment. If the answer is simply "your whole colon is slow", there is no new treatment at that point. You are sent back to the same tablets, and the remaining options are an operation, or learning to put up with it.
Most people choose the second option. They decide an operation is too big a gamble and resign themselves to years of bloating, straining and enemas. If that is where you are, the problem is not that you have run out of treatments. It is that one important question was never on the ladder. This is a gap in the system, not a failing of any one doctor.
How risky is surgery for constipation?
Riskier than most people expect, which is why so few go ahead with it. Colectomy for constipation is a big operation with a thin evidence base. The largest systematic review, part of the UK's CapaCiTY programme, pooled 40 studies and 2,045 patients. Hospital stays averaged 7 to 15 days, about one in four patients had a complication, and roughly one in seven went on to develop recurrent small-bowel obstruction in the years that followed, often needing further admissions or further surgery [6]. The authors concluded the evidence was not good enough to say who should have the operation, or which operation to do.
Sacral nerve stimulation has fared no better. The same review group found device-related problems in 13% to 34% of patients and device removal in up to 23%, and noted that three later, better-designed trials all urged more caution [7].
So if you are near the bottom of the ladder, you have probably spent years on laxatives, tried a prescription tablet or two, had a transit study and manometry, perhaps done biofeedback, and are now being asked to choose between an operation with a one-in-four complication rate and a lifetime of symptoms. Neither is a good option, and you should not have to pick one until a third has been looked at.
Here is the question to ask: has anyone checked what the bacteria in my colon are doing to its movement? For most people the honest answer is no.
Can gut bacteria cause constipation?
Yes. Your colon is not a passive tube pushed along by nerves and muscle alone. The trillions of bacteria and archaea living inside it make gases and chemical signals that talk directly to your bowel's nervous system and lining, and can speed it up or slow it down. Four of these signals matter most if you are constipated.
Methane acts as a brake. Some gut organisms convert hydrogen into methane gas. In experiments, infusing methane into the small intestine slowed transit by an average of 59% and changed the pattern of muscle contractions from propulsive to non-propulsive [8]. A meta-analysis of 1,277 people found that methane on a breath test was linked to about 3.5 times the odds of constipation [9].
Short-chain fatty acids act as an accelerator. When fibre-fermenting bacteria break down fibre they produce butyrate, propionate and acetate. These feed the cells lining the colon and stimulate the release of serotonin and other motility hormones. People with functional constipation have markedly fewer bifidobacteria and lactobacilli in their stool than healthy controls, and higher breath methane [10].
Gut bacteria regulate serotonin. Most of the body's serotonin is made in the gut, where it drives bowel movement [25], and a landmark study in Cell showed that spore-forming gut bacteria drive its production, with direct effects on gut motility [11]. Prucalopride works by stimulating serotonin (5-HT4) receptors; the microbiome is upstream of the same system.
Bacterial metabolites trigger secretion and transit. Mayo Clinic researchers showed that tryptamine, a compound made by gut bacteria, activates a receptor on the colonic lining that increases fluid secretion and speeds transit [12]. This is the same mechanism linaclotide exploits pharmacologically.
In short, your microbiome sits upstream of almost every target the prescription tablets are aimed at. Taking the tablet while ignoring the microbes is a bit like pressing the accelerator with the handbrake on, which may be exactly why the tablets only half-worked for you.
Which gut bacteria problems cause constipation?
Three patterns come up again and again in people whose constipation will not shift: too many methane producers, too few of the bacteria that keep the bowel moving, or the wrong mix. They often overlap, and each has its own treatment. You may recognise yourself in more than one.
Methane-producing overgrowth (IMO, or “methane SIBO”)
Methanobrevibacter smithii is not a bacterium but an archaeon, an ancient type of single-celled organism. It lives on the hydrogen produced by other gut microbes and turns it into methane. When it overgrows, methane bathes the bowel wall and slows it down. The American College of Gastroenterology formally recognised intestinal methanogen overgrowth (IMO) as a distinct condition in its 2020 guideline, separate from classic hydrogen-type SIBO [13]. Because methanogens live throughout the colon, not just the small bowel, IMO is a whole-gut problem, which fits with the whole-colon slowing seen on transit studies.
2. A depleted microbiome
Some people have simply lost the organisms that keep the bowel moving. Years of antibiotics, a low-fibre diet, repeated bowel preparations or a long illness can strip out the fibre-fermenting Firmicutes such as Faecalibacterium and Roseburia. Mayo Clinic research found these particular genera were associated with faster colonic transit, while methane producers tracked with slower transit [14]. Fewer fermenters means less butyrate, less serotonin signalling and a sluggish colon.
3. An imbalanced microbiome
Others have plenty of microbes, but the wrong mix. Stool profiling in constipated people shows a shifted balance between the two dominant bacterial groups, Firmicutes and Bacteroidetes, with some families over-represented and protective species under-represented [15, 16]. The science here is still maturing and there is no single agreed "constipation signature" yet [16], but a skewed profile in someone with a slow colon is a treatable finding, not a curiosity.
How do you test gut bacteria for constipation?
With a breath test and a stool sample. Neither is invasive, and both can happen alongside a transit study and manometry rather than waiting until those are done. If you have already had those tests, these can be added now.
Hydrogen and methane breath test. You drink a sugar solution (lactulose or glucose) and breathe into tubes every 15 to 20 minutes for about three hours. The North American Consensus sets a methane level of 10 parts per million or more at any point as positive for methanogen overgrowth [17]. Many older breath tests measured hydrogen only, so a "normal" breath test from years ago may never have looked for methane at all.
Stool microbiome profiling. DNA sequencing of a stool sample reports which organisms are present and in what proportions, including methanogen load, overall diversity, the Firmicutes-to-Bacteroidetes balance and the abundance of butyrate producers. These reports need expert interpretation: a result is only meaningful when read against your symptoms, transit study and breath test.
Review of the history. Antibiotic courses, proton-pump inhibitors, previous gut infections, bowel preparations, diet and travel all shape the microbiome and help explain what the tests show.
How is a gut bacteria problem treated?
By matching the treatment to what the tests show: usually first calming down what has overgrown, then rebuilding what is missing. These are the options your gastroenterologist may discuss with you.
Targeted antibiotics for methanogen overgrowth. Methane producers are hard to shift with a single drug. In a study of people with irritable bowel syndrome and methane on breath testing, the combination of rifaximin and neomycin cleared methane in 87% and improved symptoms in 85%, compared with 28% and 56% for rifaximin alone [18]. These are gut-selective antibiotics, poorly absorbed into the bloodstream, used off-label for this purpose under specialist supervision. Oral vancomycin is used in some protocols to prepare the bowel before FMT [19].
Probiotics. A meta-analysis of 14 randomised trials in 1,182 adults with functional constipation found that probiotics shortened whole-gut transit time by about 12 hours and increased stool frequency by 1.3 motions a week, with Bifidobacterium lactis strains showing the most consistent benefit [20]. The effect is modest and strain-specific, so a random supermarket probiotic is not the same thing as a chosen strain at a studied dose.
Prebiotics and fibre as food for the right organisms. Prebiotic fibres such as partially hydrolysed guar gum, inulin and resistant starch feed butyrate producers. On their own they can worsen bloating when methanogens dominate, which is one reason fibre often backfires in slow-transit constipation. After antimicrobial treatment, prebiotics are what keep the restored community fed.
Faecal microbiota transplantation (FMT). When the microbiome is depleted or badly imbalanced, the most direct fix is to replace it with a complete, healthy community from a screened donor. Australia has an unusually long track record here: the first published report of bacterial therapy relieving chronic constipation came from Sydney's Centre for Digestive Diseases in 1993 [21], and later work showed donor microbes persist for at least 24 weeks [22]. In a randomised trial of 60 people with slow-transit constipation, adding FMT to standard care lifted clinical improvement from 20% to 53% and sped up measured colonic transit [23]. A 2025 meta-analysis of nine studies found remission in about half of patients, with mostly mild and temporary side effects [24]. FMT for constipation is still a specialist treatment with an evolving evidence base, but a 50% remission rate with minor side effects compares well with the colectomy figures above.
Getting the tablets to work again. Once the microbial brake is released, prucalopride or linaclotide often work far better than they did the first time. If a tablet half-worked for you before, it may be worth a second look after the microbiome has been treated. The therapies complement each other; they do not compete.
What should happen before anyone suggests an operation?
A second line of investigation should run beside the standard one. You do not have to abandon the ladder; you need a parallel track, and you are entitled to ask for it.
The neurogastroenterology track measures your colon's nerves and muscles. Its one treatment is biofeedback, for people whose pelvic floor is the problem. For everyone else it explains the constipation without changing it. The microbiome track measures what lives in your colon and has treatments for what it finds. Neither replaces the other, and both should be finished before anyone talks to you about removing your colon.
The logic is simple. A breath test and a stool sample are inexpensive and non-invasive. A course of gut-selective antibiotics, a targeted probiotic or an FMT can be tried and judged within weeks. A colectomy is permanent, carries about a one-in-four complication rate, and leaves roughly one in seven people with recurrent bowel obstruction [6]. When a reversible treatment with a plausible mechanism has not been tried, the irreversible one should wait.
In my own practice, a meaningful share of people who arrive believing they have run out of options turn out to have methane-producing overgrowth, a stripped-out microbiome, or both. Treating that does not fix everyone. But it means that if you do eventually consider an operation, you do so knowing it was truly necessary, not because a simpler step was skipped.
What to ask your GP or gastroenterologist
If any of the following sound like you, ask whether your microbiome has been assessed before the next step is taken:
Laxatives have stopped working or now cause bloating and cramping
Prucalopride or linaclotide gave only partial relief
Your transit study showed a slow colon, your manometry was normal, and you were told there was nothing further to offer
Biofeedback has been completed, or manometry was normal, and you are still constipated
Surgery or sacral nerve stimulation has been raised as an option
You bloat badly, especially with fibre, or have ever had a positive methane breath test
See your GP promptly, whatever stage you are at, if you notice blood in your stool, unexplained weight loss, anaemia, a new change in bowel habit (particularly over 50) or have a family history of bowel cancer.
Related reading and next steps
Need to confirm your bowel lining is healthy? See direct access endoscopy.
Bloating and irregular bowels together? Read the IBS information hub.
Preparing for an appointment? See patient resources and the gastroenterology FAQ.
Based on the Northern Beaches? See gastroenterologist Northern Beaches, or contact the practice.
About the author. Dr Jeffrey Tu is a consultant gastroenterologist and hepatologist (FRACP) and conjoint lecturer at UNSW. He completed his advanced training under the late Professor Thomas Borody at the Centre for Digestive Diseases and is part of Australia's largest FMT programme, with a particular interest in methane-associated constipation and microbiome medicine. He consults at The Mater Hospital in Wollstonecraft and Northern Beaches Hospital in Frenchs Forest. A GP referral is required.
This article is general information only and is not a substitute for individual medical advice. Antibiotics, probiotics and FMT for constipation are specialist treatments and some are used outside their registered indications.
Frequently asked questions
Can constipation be caused by bacteria in the gut? Yes. Methane gas made by gut organisms slows the colon, and losing the bacteria that produce short-chain fatty acids removes one of the bowel's natural accelerators. Both have been shown in controlled studies to affect transit time [8, 9, 20].
What is methane constipation? It is constipation driven by an overgrowth of methane-producing organisms, mainly Methanobrevibacter smithii. Doctors call it intestinal methanogen overgrowth (IMO). It is diagnosed with a breath test and treated with gut-selective antibiotics, usually rifaximin combined with neomycin [13, 17, 18].
Does a normal colonoscopy rule out slow transit constipation? No. A colonoscopy looks at the lining of the bowel. It cannot measure how fast stool moves through the colon, which needs a transit study, or what the bacteria inside the colon are doing, which needs a breath test and stool profiling.
Why do laxatives stop working? Often because they are pushing against a brake. If methane is slowing the colon or the fibre-fermenting bacteria are depleted, laxatives have to work harder and harder, and fibre in particular can make bloating worse rather than better.
Can a stool test show why I'm constipated? It can show patterns that contribute: a high methanogen load, low diversity, or a shortage of butyrate-producing bacteria. On its own it does not give a diagnosis; it needs to be read alongside your symptoms, breath test and transit study by someone experienced in interpreting it.
References
Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158(5):1232–49. doi:10.1053/j.gastro.2019.12.034
Chang L, et al. AGA–ACG Clinical Practice Guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086–1106. doi:10.1053/j.gastro.2023.03.214
Camilleri M, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–54. doi:10.1056/NEJMoa0800670
Carrington EV, et al. The International Anorectal Physiology Working Group (IAPWG) recommendations: standardized testing protocol and the London classification for disorders of anorectal function. Neurogastroenterol Motil. 2020;32(1):e13679. doi:10.1111/nmo.13679
Rao SSC, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5(3):331–8. PubMed 17368232
Knowles CH, Grossi U, Chapman M, Mason J. Surgery for constipation: systematic review and practice recommendations. Results I: colonic resection. Colorectal Dis. 2017;19(Suppl 3):17–36. doi:10.1111/codi.13779
Pilkington SA, et al. Surgery for constipation: systematic review and practice recommendations. Results V: sacral nerve stimulation. Colorectal Dis. 2017;19(Suppl 3):92–100. doi:10.1111/codi.13780
Pimentel M, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1089–95. doi:10.1152/ajpgi.00574.2004
Kunkel D, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56(6):1612–8. doi:10.1007/s10620-011-1590-5
Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr. 2017;8(3):484–94. doi:10.3945/an.116.014407
Yano JM, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–76. doi:10.1016/j.cell.2015.02.047
Bhattarai Y, et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe. 2018;23(6):775–85. doi:10.1016/j.chom.2018.05.004
Pimentel M, et al. ACG Clinical Guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–78. doi:10.14309/ajg.0000000000000501
Parthasarathy G, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150(2):367–79. doi:10.1053/j.gastro.2015.10.005
Zhu L, et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014;46(18):679–86. doi:10.1152/physiolgenomics.00082.2014
Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut microbiota and chronic constipation: a review and update. Front Med (Lausanne). 2019;6:19. doi:10.3389/fmed.2019.00019
Rezaie A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–84. doi:10.1038/ajg.2017.46
Low K, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547–50. doi:10.1097/MCG.0b013e3181c64c90
Ge X, et al. Short-term efficacy of fecal microbiota transplantation combined with soluble dietary fiber and probiotics in the treatment of slow transit constipation. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(12):1355–9. PubMed 28000190
Dimidi E, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075–84. doi:10.3945/ajcn.114.089151
Andrews PJ, Borody TJ. "Putting back the bugs": bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med J Aust. 1993;159(9):633–4. doi:10.5694/j.1326-5377.1993.tb138063.x
Grehan MJ, Borody TJ, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010;44(8):551–61. doi:10.1097/MCG.0b013e3181e5d06b
Tian H, et al. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLoS One. 2017;12(2):e0171308. doi:10.1371/journal.pone.0171308
Wang K, et al. Fecal microbiota transplantation for chronic constipation: a systematic review and meta-analysis of clinical efficacy, safety, and microbial dynamics. Front Microbiol. 2025;16:1604571. doi:10.3389/fmicb.2025.1604571
Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414. doi:10.1053/j.gastro.2006.11.002
Comments